Accuray Incorporated — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2024; filed May 8, 2024. The filing compares results with the periods ended March 31, 2023. Although the request metadata says “2023 Q3,” the filing itself covers 2024 Q3.
Business context
Accuray develops, sells, and supports radiation therapy systems, including CyberKnife and TomoTherapy/Radixact, and provides related services. It operates worldwide and reports one segment. Its 49%-owned China joint venture manufactures and sells radiation oncology systems in China.
Key financial results
| Metric | Three months ended Mar. 31, 2024 | Nine months ended Mar. 31, 2024 |
|---|---|---|
| Revenue | $101.1 million, down 14% | $312.3 million, down 5% |
| Product revenue | $49.6 million, down 21% | $154.5 million, down 10% |
| Service revenue | $51.5 million, down 7% | $157.8 million, down 1% |
| Gross profit / margin | $29.1 million / 28.7% | $104.5 million / 33.5% |
| Operating income (loss) | $(4.6) million | $(6.3) million |
| Net income (loss) | $(6.3) million; $(0.06) per share | $(18.9) million; $(0.19) per share |
| Operating cash flow | Not presented separately for the quarter | $(21.8) million |
At March 31, 2024, cash and cash equivalents were $60.5 million. Current assets were $313.9 million and current liabilities $198.4 million. Debt had a $175.5 million principal balance and $173.5 million net carrying value, including $100 million of 3.75% convertible notes due 2026, a $65.5 million term loan, and $10 million drawn on a $40 million revolver. Stockholders’ equity was $41.1 million and accumulated deficit was $521.1 million.
Changes versus the prior comparable periods
- Quarterly revenue fell $16.9 million, mainly from lower system shipments in the Americas and China and lower Americas service revenue. Year-to-date revenue declined $17.1 million.
- Quarterly gross margin decreased to 28.7% from 32.8%; nine-month margin decreased to 33.5% from 35.3%. The filing attributes lower gross profit principally to reduced shipment volume and cites inflation, component costs, freight, and logistics as continuing pressures.
- The company recorded a quarterly net loss compared with net income of $0.6 million in the prior-year quarter. The nine-month net loss widened from $6.7 million.
- Operating cash flow swung from $6.7 million provided in the prior-year nine-month period to $21.8 million used. Inventory increased $22.7 million in cash-flow terms, partly reflecting purchases to meet expected demand.
- Americas revenue fell 38% in the quarter and 27% year to date. Nine-month EIMEA and China revenue increased 6% and 20%, respectively; Japan and Asia Pacific excluding China declined.
- Gross orders rose to $89.1 million for the quarter and $246.7 million year to date. Backlog was $503.2 million, versus $506.6 million a year earlier. The company reported book-to-bill ratios of 1.8 for the quarter and 1.6 year to date.
Outlook, risks, and unusual items
- Management expects to have sufficient cash resources and anticipated cash flows to fund operations for at least 12 months. This is subject to uncertainty, including operating performance and debt covenant compliance.
- Reduced U.S. customer budgets, lower capital priority for radiotherapy equipment, and longer installation timelines hurt quarterly revenue; management expects this pressure to continue through at least fiscal 2026. Supply-chain, inflation, freight, and logistics costs are expected to weigh on margins and net results through at least the remainder of calendar 2024, potentially longer. Delivery and installation delays may also continue during 2024.
- On April 25, 2024, after quarter-end, Accuray amended its credit agreement to revise the Consolidated EBITDA calculation to maintain covenant compliance as of March 31, 2024. Substantially all company assets secure the credit facilities; a future covenant default could accelerate debt. Management said the availability and cost of any future waiver or amendment cannot be assured.
- A cost-savings initiative announced in October 2023 eliminated approximately 5.9% of the global workforce. Nine-month restructuring charges were $2.6 million; $0.2 million remained accrued at March 31.
- Open system sales contracts were $849.6 million; management estimates approximately 24% may never result in revenue. Of $959.9 million in remaining performance obligations, it estimates 27%–30% of the $896.1 million excluding long-term warranty and post-warranty services will be recognized within 12 months.
- Management performed an interim goodwill impairment test after identifying triggering events, including lower cash flows and a downward adjustment to annual guidance; it found no impairment as of March 31, 2024.
- Other key exposures include dependence on scarce or single-source components, foreign exchange, customer cancellations and installation delays, customer credit risk, competition, regulatory requirements, and geopolitical and China-related risks. Management reported no probable and reasonably estimable material losses from current litigation.
Important facts for investors to verify
- Whether the April 25 credit amendment and subsequent results support ongoing covenant compliance, liquidity, and the 12-month funding assessment.
- Whether system shipments and installations recover, particularly in the Americas, and how the stated fiscal 2026 demand pressure affects revenue.
- Whether order growth converts into revenue: monitor backlog age-outs, cancellations, customer readiness, and the estimated 24% of open system contracts that may not produce revenue.
- Whether inventory levels, operating cash use, and gross margins improve as supply-chain, freight, and material-cost pressures evolve.
- How much revenue and receivables are associated with the China joint venture and other major customers, and whether foreign-exchange movements materially affect results.